the activity of a therapeutic drug against paget 's disease is judged by a reduction in the level of hydroxyprolinuria and of alkaline phosphatasaemia , these being the metabolic signs of the bone changes , and by a decrease in bone pain which may accompany the bone changes in paget 's disease .
C0262950
bone
C0029401
bone